About Turn Therapeutics
Who We Are
Turn Therapeutics is a concept to approval R&D biotech organization dedicated to reducing the human and economic cost of infection and skin disease. Turn Therapeutics was founded in 2015 with a goal of reducing antibiotic resistance through best in class acute and chronic wound care products. We have not been diverted from that goal, and have continued to uncover additional diseases and medical arenas that our technology will serve. Our core mission is to leverage our expertise in drug delivery technology to create disruptive products for high need indications.
Dedicated to reducing the human and economic cost of infection and skin disease.
How does true innovation happen? By defying conventional wisdom. By setting off in an unexpected direction. By having the courage to imagine something better. At Turn Therapeutics, we consider it our mission to challenge the inertia of standardized medicine and embark on an enterprise of discovery.
We’ve only just begun: our groundbreaking PermaFusion™ Technology is the driving force behind two unique infectious disease therapies in our pipeline, as well as tried and trusted wound and dermatitis management tools. The technology itself is a product of a years’ long battle with a severe infection that Founder and CEO, Bradley Burnam, acquired while making his hospital rounds as a medical device salesperson. The infection required over a dozen reconstructive surgeries and months of slow, painful healing. The topical antibiotics Bradley was prescribed were simply not helping him heal. It was this infection that drove Bradley to imagine a better medicine. The result was PermaFusion™ Technology and our first FDA Cleared product offering, Hexagen™ Wound Dressing, but that was just the beginning.
Our work—aimed at discovering cures—is a constant evolution and a challenge to the status quo. If modern medicine is the book, we will be the next breakthrough chapter.
Regulatory and formulation expert. Creator of the PermaFusion™ water-in- oil delivery system, Hexagen™, AtopX™, GX-03, and OV-02. 15 years experience in medical devices and pharmaceuticals, including management and sales for Fortune 100 companies.
Neil Ghodadra, MD
Executive VP Business Development
Duke and Rush trained, board-certified orthopedic surgeon. Business and implementation specialist.
15 years of high-level banking with top- tier banks, investor relations, and transactional experience.
Earlean (Nikki) Hunter
Over 20 years of accounting experience. Specializing in Cost Accounting and Nonprofit Organizations. Nikki is also a certified cGMP compliance expert.